Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-κB but is related to downregulation of initiator caspases and DR4

Oncogene volume 26, pages 3364–3377 (2007)Cite this article

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has attracted considerable attention as a novel anticancer agent. However, its efficiency may be diminished by occurring resistance in cancer cells. The mechanisms of TRAIL resistance in melanoma are still unsolved. Here we show for the first time that TRAIL-induced activation of NF-κB occurs in apoptosis-sensitive melanoma cell lines through TRAIL receptor 1/death receptor 4 (TRAIL-R1/DR4), whereas TRAIL failed to activate nuclear factor kappa B (NF-κB) in melanoma cells positive only for TRAIL receptor 2/death receptor 5 (TRAIL-R2/DR5). However, activation of NF-κB by TRAIL was not associated with enhanced expression of antiapoptotic factors: cellular FLICE-inhibitory protein (c-FLIP), Bcl-xL, X-linked inhibitor of apoptosis protein (XIAP), Survivin, Livin. Rather in one of the cell lines, TRAIL induced the downregulation of DR4. In an established cell culture model for TRAIL resistance and regained TRAIL sensitivity, resistance was neither associated with increased NF-κB activity by TRAIL nor by an increased expression of antiapoptotic proteins. However, significant downregulation of caspase-8, caspase-10 and of DR4 was characteristic for TRAIL-resistant, DR4-positive melanoma cells, and regained TRAIL sensitivity coincided with re-expression of these factors. Sensitivity was also largely retained after their exogenous overexpression. Thus, initiator caspases and DR4 rather than NF-κB may control melanoma cell sensitivity to TRAIL, and strategies, which result in their upregulation, may be useful for enhancement of TRAIL sensitivity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

Abbreviations

TRAIL:

tumor necrosis factor-related apoptosis-inducing ligand

TRAIL-R1/DR4:

TRAIL receptor 1/death receptor 4

TRAIL-R2/DR5:

TRAIL receptor 2/death receptor 5

NF-κB:

nuclear factor kappa B

References

  • Ashkenazi A . (2002). Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2: 420–430.

    Article  CAS  Google Scholar 

  • Bai J, Sui J, Demirjian A, Vollmer Jr CM, Marasco W, Callery MP . (2005). Predominant Bcl-xL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer Res 65: 2344–2352.

    Article  CAS  Google Scholar 

  • Chawla-Sarkar M, Leaman DW, Jacobs BS, Borden EC . (2002). IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis. J Immunol 169: 847–855.

    Article  CAS  Google Scholar 

  • Chen X, Kandasamy K, Srivastava RK . (2003). Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling. Cancer Res 63: 1059–1066.

    CAS  PubMed  Google Scholar 

  • Di Pietro R, Zauli G . (2004). Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol 201: 331–340.

    Article  CAS  Google Scholar 

  • Eberle J, Fecker LF, Hossini AM, Wieder T, Daniel PT, Orfanos CE et al. (2003). CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants. Oncogene 22: 9131–9141.

    Article  CAS  Google Scholar 

  • Eberle J, Weitmann S, Thieck O, Pech H, Paul M, Orfanos CE . (1999). Downregulation of endothelin B receptor in human melanoma cell lines parallel to differentiation genes. J Invest Dermatol 112: 925–932.

    Article  CAS  Google Scholar 

  • Eggert A, Grotzer MA, Zuzak TJ, Wiewrodt BR, Ho R, Ikegaki N et al. (2001). Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res 61: 1314–1319.

    CAS  PubMed  Google Scholar 

  • Ehrhardt H, Fulda S, Schmid I, Hiscott J, Debatin KM, Jeremias I . (2003). TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappa B. Oncogene 22: 3842–3852.

    Article  CAS  Google Scholar 

  • Fecker LF, Geilen CC, Tchernev G, Trefzer U, Assaf C, Kurbanov BM et al. (2006). Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis. J Invest Dermatol 126: 1366–1371.

    Article  CAS  Google Scholar 

  • Fischer U, Schulze-Osthoff K . (2005). Apoptosis-based therapies and drug targets. Cell Death Differ 12 (Suppl 1): 942–961.

    Article  CAS  Google Scholar 

  • Franco AV, Zhang XD, Van Berkel E, Sanders JE, Zhang XY, Thomas WD et al. (2001). The role of NF-kappa B in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells. J Immunol 166: 5337–5345.

    Article  CAS  Google Scholar 

  • Fulda S, Debatin KM . (2006). 5-Aza-2′-deoxycytidine and IFN-gamma cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8. Oncogene 25: 5125–5133.

    Article  CAS  Google Scholar 

  • Fulda S, Kufer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin KM . (2001). Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 20: 5865–5877.

    Article  CAS  Google Scholar 

  • Ganten TM, Koschny R, Haas TL, Sykora J, Li-Weber M, Herzer K et al. (2005). Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology 42: 588–597.

    Article  CAS  Google Scholar 

  • Harper N, Farrow SN, Kaptein A, Cohen GM, MacFarlane M . (2001). Modulation of tumor necrosis factor apoptosis-inducing ligand-induced NF-kappa B activation by inhibition of apical caspases. J Biol Chem 276: 34743–34752.

    Article  CAS  Google Scholar 

  • He Q, Huang Y, Sheikh MS . (2004). Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells. Oncogene 23: 2554–2558.

    Article  CAS  Google Scholar 

  • Ishimura N, Isomoto H, Bronk SF, Gores GJ . (2006). Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am J Physiol Gastrointest Liver Physiol 290: G129–G136.

    Article  CAS  Google Scholar 

  • Ivanov VN, Bhoumik A, Ronai Z . (2003). Death receptors and melanoma resistance to apoptosis. Oncogene 22: 3152–3161.

    Article  CAS  Google Scholar 

  • Jin Z, McDonald III ER, Dicker DT, El Deiry WS . (2004). Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J Biol Chem 279: 35829–35839.

    Article  CAS  Google Scholar 

  • Johnson TR, Stone K, Nikrad M, Yeh T, Zong WX, Thompson CB et al. (2003). The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene 22: 4953–4963.

    Article  CAS  Google Scholar 

  • Karin M, Ben Neriah Y . (2000). Phosphorylation meets ubiquitination: the control of NF-[kappa] B activity. Annu Rev Immunol 18: 621–663.

    Article  CAS  Google Scholar 

  • Karin M, Greten FR . (2005). NF-kappa B: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5: 749–759.

    Article  CAS  Google Scholar 

  • Karin M, Lin A . (2002). NF-kappa B at the crossroads of life and death. Nat Immunol 3: 221–227.

    Article  CAS  Google Scholar 

  • Kelley SK, Ashkenazi A . (2004). Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 4: 333–339.

    Article  CAS  Google Scholar 

  • Kim K, Fisher MJ, Xu SQ, El Deiry WS . (2000). Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 6: 335–346.

    CAS  PubMed  Google Scholar 

  • Kischkel FC, Lawrence DA, Tinel A, LeBlanc H, Virmani A, Schow P et al. (2001). Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem 276: 46639–46646.

    Article  CAS  Google Scholar 

  • Kurbanov BM, Geilen CC, Fecker LF, Orfanos CE, Eberle J . (2005). Efficient TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Invest Dermatol 125: 1010–1019.

    Article  CAS  Google Scholar 

  • LeBlanc HN, Ashkenazi A . (2003). Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 10: 66–75.

    Article  CAS  Google Scholar 

  • Lens MB, Dawes M . (2004). Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 150: 179–185.

    Article  CAS  Google Scholar 

  • Leverkus M, Sprick MR, Wachter T, Denk A, Brocker EB, Walczak H et al. (2003a). TRAIL-induced apoptosis and gene induction in HaCaT keratinocytes: differential contribution of TRAIL receptors 1 and 2. J Invest Dermatol 121: 149–155.

    Article  CAS  Google Scholar 

  • Leverkus M, Sprick MR, Wachter T, Mengling T, Baumann B, Serfling E et al. (2003b). Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation. Mol Cell Biol 23: 777–790.

    Article  CAS  Google Scholar 

  • Li-Weber M, Krammer PH . (2003). Function and regulation of the CD95 (APO-1/Fas) ligand in the immune system. Semin Immunol 15: 145–157.

    Article  CAS  Google Scholar 

  • Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R et al. (2001). TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 98: 795–804.

    Article  CAS  Google Scholar 

  • Nguyen T, Zhang XD, Hersey P . (2001). Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Clin Cancer Res 7: 966s–973s.

    CAS  PubMed  Google Scholar 

  • Ravi R, Bedi A . (2004). NF-kappa B in cancer – a friend turned foe. Drug Resist Update 7: 53–67.

    Article  CAS  Google Scholar 

  • Ravi R, Bedi GC, Engstrom LW, Zeng Q, Mookerjee B, Gelinas C et al. (2001). Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappa B. Nat Cell Biol 3: 409–416.

    Article  CAS  Google Scholar 

  • Rudner J, Jendrossek V, Lauber K, Daniel PT, Wesselborg S, Belka C . (2005). Type I and type II reactions in TRAIL-induced apoptosis – results from dose–response studies. Oncogene 24: 130–140.

    Article  CAS  Google Scholar 

  • Secchiero P, Milani D, Gonelli A, Melloni E, Campioni D, Gibellini D et al. (2003). Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and TNF-alpha promote the NF-kappaB-dependent maturation of normal and leukemic myeloid cells. J Leukoc Biol 74: 223–232.

    Article  CAS  Google Scholar 

  • Singh TR, Shankar S, Chen X, Asim M, Srivastava RK . (2003). Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res 63: 5390–5400.

    CAS  PubMed  Google Scholar 

  • Soengas MS, Lowe SW . (2003). Apoptosis and melanoma chemoresistance. Oncogene 22: 3138–3151.

    Article  CAS  Google Scholar 

  • Sprick MR, Rieser E, Stahl H, Grosse-Wilde A, Weigand MA, Walczak H . (2002). Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO J 21: 4520–4530.

    Article  CAS  Google Scholar 

  • von Haefen C, Gillissen B, Hemmati PG, Wendt J, Guner D, Mrozek A et al. (2004). Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway. Oncogene 23: 8320–8332.

    Article  CAS  Google Scholar 

  • Voorhees PM, Dees EC, O’Neil B, Orlowski RZ . (2003). The proteasome as a target for cancer therapy. Clin Cancer Res 9: 6316–6325.

    CAS  PubMed  Google Scholar 

  • Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M et al. (1999). Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157–163.

    Article  CAS  Google Scholar 

  • Wang S, El Deiry WS . (2003). TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22: 8628–8633.

    Article  CAS  Google Scholar 

  • Wang SH, Mezosi E, Wolf JM, Cao Z, Utsugi S, Gauger PG et al. (2004). IFNgamma sensitization to TRAIL-induced apoptosis in human thyroid carcinoma cells by upregulating Bak expression. Oncogene 23: 928–935.

    Article  CAS  Google Scholar 

  • Wendt J, von Haefen C, Hemmati P, Belka C, Dorken B, Daniel PT . (2005). TRAIL sensitizes for ionizing irradiation-induced apoptosis through an entirely Bax-dependent mitochondrial cell death pathway. Oncogene 24: 4052–4064.

    Article  CAS  Google Scholar 

  • Zauli G, Sancilio S, Cataldi A, Sabatini N, Bosco D, Di Pietro R . (2005). PI-3K/Akt and NF-kappaB/IkappaBalpha pathways are activated in Jurkat T cells in response to TRAIL treatment. J Cell Physiol 202: 900–911.

    Article  CAS  Google Scholar 

  • Zhang L, Fang B . (2005). Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 12: 228–237.

    Article  CAS  Google Scholar 

  • Zhang XD, Borrow JM, Zhang XY, Nguyen T, Hersey P . (2003). Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria. Oncogene 22: 2869–2881.

    Article  CAS  Google Scholar 

  • Zhang XD, Wu JJ, Gillespie S, Borrow J, Hersey P . (2006). Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by Cisplatin. Clin Cancer Res 12: 1355–1364.

    Article  CAS  Google Scholar 

  • Zhu H, Guo W, Zhang L, Wu S, Teraishi F, Davis JJ et al. (2005). Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation. Cancer Biol Ther 4: 781–786.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The study was supported by the Deutsche Krebshilfe (grant 10–1434-Eb 2), by the Berliner Stiftung für Dermatologie and by a scholarship of the Islamic Development Bank.

Author information

Authors and Affiliations

  1. Department of Dermatology and Allergy, Skin Cancer Center, Charité – Universitätsmedizin Berlin, Berlin, Germany

    B M Kurbanov, L F Fecker, C C Geilen, W Sterry & J Eberle

Authors
  1. B M Kurbanov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L F Fecker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C C Geilen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W Sterry
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Eberle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J Eberle.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kurbanov, B., Fecker, L., Geilen, C. et al. Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-κB but is related to downregulation of initiator caspases and DR4. Oncogene 26, 3364–3377 (2007). https://doi.org/10.1038/sj.onc.1210134

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1210134

Keywords

This article is cited by

Search

Advanced search

Quick links